Early detection saves lives Melanoma is one of the most aggressive skin cancers – but also highly treatable when detected early. Nevisense supports dermatologists with objective, non-invasive diagnostic data to improve accuracy and confidence in clinical decision-making.
Rule out the risk of missing a melanoma with 97% sensitivity.
AI-powered diagnostic support
Nevisense uses electrical impedance spectroscopy (EIS) combined with AI algorithms to detect structural changes in skin tissue. It provides a Nevisense score that helps clinicians evaluate suspicious lesions beyond visual inspection.
The Nevisense Melanoma score
The measurement provides 700 data points that are analyzed by the Nevisense proprietary algorithm (AI). Giving the clinician an actionable risk assessment score between 0-10. 0-3 indicate a negative score with a 99% negative predictive value for melanoma (ref). 4-10 indicate a positive score with an increasing level of risk for melanoma.
Supporting dermatologists and skin cancer specialists
Nevisense is a valuable tool for: • Dermatologists and clinics focusing on enhanced melanoma management and patient care.
"Nevisense has changed the way I evaluate suspicious lesions. It gives me the confidence in the decisions I make every day".
DR: MARGARETA F. NILSSON
Dermatologist, Hudläkargruppen, Karolinska Institutet, Stockholm, Sweden
Increased diagnostic confidence Clinical studies show that Nevisense improves sensitivity with 97 % in melanoma detection, reduces unnecessary biopsies with 14% and supports more consistent evaluations between professionals.
Seamless clinical integration The measurement process is non-invasive and easy to integrate into dermatology workflows, with results at the point of care for more well informed decisions.
BOOK A DEMO
Discover how Nevisense can enhance your melanoma management
Book a personalized demonstration to learn how Nevisense can complement your current diagnostic process and provide objective support for clinical decision-making.
Rule out melanoma with 99% NPV
